• Molecular NamePhenelzine
  • SynonymNA
  • Weight136.198
  • Drugbank_IDDB00780
  • ACS_NO51-71-8
  • Show 3D model
  • LogP (experiment)0.769
  • LogP (predicted, AB/LogP v2.0)0.84
  • pkaN/A
  • LogD (pH=7, predicted)0.04
  • Solubility (experiment)29.1 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)0.0
  • LogSw (predicted, AB/LogsW2.0)9.63
  • Sw (mg/ml) (predicted, ACD/Labs)9.32
  • No.of HBond Donors3
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds3
  • TPSA38.05
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn irreversible and nonselective and monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class which is used as an antidepressant and anxiolytic.
  • Absorption_valueN/A
  • Absorption (description)Readily absorbed after oral administration.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic. Acetylation of phenelzine appears to be a minor metabolic pathway. Beta-phenylethylamine is a metabolite of phenelzine, and there is indirect evidence that phenelzine may also be ring-hydroxylated and N-methylated.
  • Half life7 h
  • ExcretionUrine
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include drowsiness, dizziness, faintness, irritability, hyperactivity, agitation, severe headache, hallucinations, trismus, opisthotonos, convulsions and coma, rapid and irregular pulse, hypertension, hypotension and vascular collapse, precordial pain, respiratory depression and failure, hyperpyrexia, diaphoresis, and cool, clammy skin.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A